Patents by Inventor Richard Duane Johnston
Richard Duane Johnston has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240368193Abstract: The present invention provides compounds of the formula: wherein A, Z, G, R1, R2, and R4 are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.Type: ApplicationFiled: March 29, 2024Publication date: November 7, 2024Inventors: Adedoyin David ABRAHAM, Alberto VALERO DE LA CRUZ, Alicia MARCOS LLORENTE, Alvaro ENRIQUEZ GARCIA, Andrew DILGER, Deqi GUO, Desta BUME, Frederic LAURENT CORDIER, Gaiying ZHAO, Isabel ROJO GARCIA, James Robert HENRY, Jason Eric LAMAR, Jolie Anne BASTIAN, Maria Lourdes PRIETO VALLEJO, Mario BARBERIS, Matthew Patrick BAUMGARTNER, Miguel GARZÓN SANZ, Pablo GARCIA LOSADA, Ramkumar RAJAMANI, Richard Duane JOHNSTON, Robert HAZLITT, Santiago CARBALLARES MARTIN, Sean ARONOW, Shane Michael WALLS, Sonia Maria GUTIERREZ SANFELICIANO, Steven ANDREWS, Timothy Scott KERCHER, Victoriano MOLERO FLÓREZ, Wenceslao LUMERAS AMADOR, William Rush SCAGGS, Juan Antonio RINCON CABEZUDO, Julián PRIEGO SOLER, Xiaohong CHEN
-
Publication number: 20240228511Abstract: The present invention provides compounds of the formula where R1, R2, R3, R4a, R4b, R4c, R5, R6, X, Y, and Z are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.Type: ApplicationFiled: June 8, 2022Publication date: July 11, 2024Inventors: David Anthony BARDA, Joshua Ryan CLAYTON, Jeffry Bernard FRANCISKOVICH, Kelly Wayne FURNESS, Douglas Linn GERNERT, James Robert HENRY, Richard Duane JOHNSTON, Spencer Brian JONES, Jason Eric LAMAR, Adam Marc LEVINSON, Curren Tapfuma MBOFANA, Michael John RODRIQUEZ, Almudena RUBIO, Chong SI, Gaiying ZHAO, Mohammed Sadegh ZIA-EBRAHIMI
-
Patent number: 11999722Abstract: The present invention provides a compound of Formula I. or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.Type: GrantFiled: September 17, 2021Date of Patent: June 4, 2024Assignee: ELI LILLY AND COMPANYInventors: David Andrew Coates, Timothy Barrett Durham, Richard Duane Johnston, Steven Marc Massey, Patrick Gianpietro Spinazze, Douglas Richard Stack, James Lee Toth
-
Publication number: 20240043451Abstract: The present invention provides compounds of the formula: wherein A, B, D1, X, Y, Z, G, R1, R2, and R3a are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.Type: ApplicationFiled: March 24, 2023Publication date: February 8, 2024Inventors: David Anthony BARDA, Jolie Anne BASTIAN, Kelly Wayne FURNESS, Deqi GUO, James Robert HENRY, Richard Duane JOHNSTON, Jason Eric LAMAR, Tao LIU, Michael John RODRIGUEZ, Almudena RUBIO, Chong SI, Gaiying ZHAO, Mohammad Sadegh ZIA-EBRAHIMI, Matthew Patrick BAUMGARTNER, Isabel ROJO, Mario BARBERIS, Santiago CARBALLARES MARTIN, Pablo GARCIA LOSADA, Sonia Maria GUTIERREZ SANFELICIANO, Wenceslao LUMERAS AMADOR, Victoriano MOLERO FLOREZ, Maria Lourdes PRIETO VALLEJO
-
Publication number: 20230167087Abstract: The present invention provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula (I) for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.Type: ApplicationFiled: February 4, 2021Publication date: June 1, 2023Inventors: Timothy Barrett DURHAM, Junliang HAO, Richard Duane JOHNSTON
-
Publication number: 20220017496Abstract: The present invention provides a compound of Formula I. or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.Type: ApplicationFiled: September 17, 2021Publication date: January 20, 2022Inventors: David Andrew COATES, Timothy Barrett DURHAM, Richard Duane JOHNSTON, Steven Marc MASSEY, Patrick Gianpietro SPINAZZE, Douglas Richard STACK, James Lee TOTH
-
Patent number: 11180503Abstract: The present invention provides a compound of Formula (I), wherein X is H or C1-C3 alkyl optionally substituted with hydroxyl; Y is H, hydroxy, or methyl; R is ethyl, n-propyl, cyclopropyl, or Formula (II); and A is methyl, cyclopropyl or trifluoromethyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X and Y are both H and R is n-propyl, then A is other than methyl; for use as a human PDE1 inhibitor.Type: GrantFiled: July 26, 2018Date of Patent: November 23, 2021Assignee: ELI LILLY AND COMPANYInventors: Michael James Genin, William Glen Holloway, Richard Duane Johnston, John Richard Morphy, Qing Shi
-
Patent number: 11124500Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.Type: GrantFiled: June 16, 2020Date of Patent: September 21, 2021Assignee: Eli Lilly and CompanyInventors: David Andrew Coates, Timothy Barrett Durham, Richard Duane Johnston, Steven Marc Massey, Patrick Gianpietro Spinazze, Douglas Richard Stack, James Lee Toth
-
Publication number: 20200392118Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.Type: ApplicationFiled: June 16, 2020Publication date: December 17, 2020Inventors: David Andrew COATES, Timothy Barrett DURHAM, Richard Duane JOHNSTON, Steven Marc MASSEY, Patrick Gianpietro SPINAZZE, Douglas Richard STACK, James Lee TOTH
-
Publication number: 20200123154Abstract: The present invention provides a compound of Formula (I), wherein X is H or C1-C3 alkyl optionally substituted with hydroxyl; Y is H, hydroxy, or methyl; R is ethyl, n-propyl, cyclopropyl, or Formula (II); and A is methyl, cyclopropyl or trifluoromethyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X and Y are both H and R is n-propyl, then A is other than methyl; for use as a human PDE1 inhibitor.Type: ApplicationFiled: July 26, 2018Publication date: April 23, 2020Applicant: Eli Lilly and CompanyInventors: Michael James Genin, William Glen Holloway, Richard Duane Johnston, John Richard Morphy, Qing Shi
-
Patent number: 9637495Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 5, 2016Date of Patent: May 2, 2017Assignee: Eli Lilly and CompanyInventors: David Andrew Coates, Kevin Charles Fortner, Richard Duane Johnston, Steven Marc Massey, Jason Kenneth Myers, Qing Shi, Miles Goodman Siegel
-
Publication number: 20170044163Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 5, 2016Publication date: February 16, 2017Inventors: David Andrew Coates, Kevin Charles Fortner, Richard Duane Johnston, Steven Marc Massey, Jason Kenneth Myers, Qing Shi, Miles Goodman Siegel
-
Patent number: 7612067Abstract: The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.Type: GrantFiled: March 20, 2006Date of Patent: November 3, 2009Assignee: Eli Lilly and CompanyInventors: Heather Janelle Barbosa, Elizabeth Aaron Collins, Chafiq Hamdouchi, Erik James Hembre, Philip Arthur Hipskind, Richard Duane Johnston, Jianliang Lu, Michael John Rupp, Takako Takakuwa, Richard Craig Thompson
-
Patent number: 7544812Abstract: The present invention is directed to compounds represented by the following structural Formula (I), (a) R1 is selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C1-C8 alkyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, C3-C6 cycloalkylaryl-C0-2-alkyl, and —CH2—C(O)—R17-R18, wherein R17 is O or NH and R18 is optionally substituted benzyl; (b) R2 is selected from the group consisting of C1-C6 alkyl, C1-C6 alkenyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, C1-C4 alkyl sulfonamide, C1-C4 alkyl amide, OR10 and C3-C6 cycloalkyl; (c) W is O or S; (d) X is an optionally substituted C1-C5 alkylene linker wherein one carbon atom of the linker may optionally be replaced with O, NH, S, and optionally two carbons together may form a double bond; (e) Y is selected from the group consisting of C, O, S, NH and a single bond; and (f) E is selected from the group consisting of C(R3)(R4)A, A, and a substituted or unsubstituted group selected from the group consisting of (CH2)n COOR19.Type: GrantFiled: November 26, 2002Date of Patent: June 9, 2009Assignee: Eli Lilly and CompanyInventors: Tracey Ann Gibson, Richard Duane Johnston, Nathan Bryan Mantlo, Richard Craig Thompson, Leonard Larry Winneroski, Yanping Xu, Xiaodong Wang
-
Publication number: 20090062358Abstract: The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is a substituted or unsubstituted group selected from C1-C8 alkyl, aryl-C0-2-alkyl, heteroaryl-C0-2-alkyl, C3-C6 cycloalkylaryl-C0-2-alkyl or phenyl. W is O or S. R2 is H or a substituted or unsubstituted group selected from C1-C6 alkyl, C3-C6 cycloalkyl and heteroaryl. X is a C2-C5 alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S. Y is C, O, S, NH or a single bond. Furthermore, E is (CH2)nCOOH, wherein n is 0, 1, 2 or 3, or C(R3)(R4)A, wherein A is an acidic functional group such as carboxyl, carboxamide substituted or unsubstituted sulfonamide, or substituted or unsubstituted tetrazole. R3 is H, saturated or unsaturated C1-C5 alkyl, C1-C5 alkoxy.Type: ApplicationFiled: July 26, 2007Publication date: March 5, 2009Inventors: Ivan Collado Cano, Samuel James Dominianni, Garret Jay Etgen, JR., Cristina Garcia-Paredes, Richard Duane Johnston, Michael Edward Letourneau, Nathan Bryan Mantlo, Michael John Martinelli, Daniel Ray Mayhugh, Ashraf Saeed, Richard Craig Thompson, Xiaodong Wang, David Scott Coffey, Christopher Randall Schmid, Jeffrey Thomas Vicenzi, Yanping Xu
-
Publication number: 20080113978Abstract: The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.Type: ApplicationFiled: March 20, 2006Publication date: May 15, 2008Inventors: Heather Janelle Barbosa, Elizabeth Aaron Collins, Chafip Hamdouchi, Erik James Hembre, Philip Arthur Hipskind, Richard Duane Johnston, Jianliang Lu, Michael John Rupp, Takako Takakuwa, Richard Craig Thompson
-
Patent number: 7304062Abstract: The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is a substituted or unsubstituted group selected from C1-C8 alkyl, aryl-C0-2-alkyl, heteroaryl-C0-2-alkyl, C3-C6 cycloalkylaryl-C0-2-alkyl or phenyl. W is O or S. R2 is H or a substituted or unsubstituted group selected from C1-C6 alkyl, C3-C6 cycloalkyl and heteroaryl. X is a C2-C5 alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S. Y is C, O, S, NH or a single bond. Furthermore, E is (CH2)nCOOH, wherein n is 0, 1, 2 or 3, or C(R3)(R4)A, wherein A is an acidic functional group such as carboxyl, carboxamide substituted or unsubstituted sulfonamide, or substituted or unsubstituted tetrazole. R3 is H, saturated or unsaturated C1-C5 alkyl, C1-C5 alkoxy.Type: GrantFiled: November 9, 2001Date of Patent: December 4, 2007Assignee: Eli Lilly and CompanyInventors: Samuel James Dominianni, Garret Jay Etgen, Richard Duane Johnston, Nathan Bryan Mantlo, Daniel Ray Mayhugh, Ashraf Saeed, Richard Craig Thompson, Xiaodong Wang, Christopher Randall Schmid, Yanping Xu
-
Patent number: 7205321Abstract: The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C1–C8 alkyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, and C3–C6 cycloalkylaryl-C0-2-alkyl; W is O or S; X is an optionally substituted C1–C5 alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S; Y is C, O, S, NH or a single bond; E is C(R3)(R4)A or AType: GrantFiled: November 13, 2002Date of Patent: April 17, 2007Assignee: Eli Lilly and CompanyInventors: Richard Duane Johnston, Nathan Bryan Mantlo, Richard Craig Thompson
-
Publication number: 20040235912Abstract: The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C1-C8 alkyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, and C3-C6 cycloalkylaryl-C0-2-alkyl; W is O or S; X is an optionally substituted C1-C5 alkylene linker wherein one carbon atom the linker may be replaced with O, NH or S; Y is C, O, S, NH or a single bond; E is C(R3)(R4)A or A.Type: ApplicationFiled: May 10, 2004Publication date: November 25, 2004Inventors: Richard Duane Johnston, Nathan Bryan Mantlo, Richard Craig Thompson
-
Publication number: 20040102500Abstract: The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is a substituted or unsubstituted group selected from C1-C8 alkyl, aryl-C0-2-alkyl, heteroaryl-C0-2-alkyl, C3-C6 cycloalkylaryl-C0-2-alkyl or phenyl. W is O or S. R2 is H or a substituted or unsubstituted group selected from C1-C6 alkyl, C3-C6 cycloalkyl and heteroaryl. X is a C2-C5 alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S. Y is C, O, S, NH or a single bond. Furthermore, E is (CH2)nCOOH, wherein n is 0, 1, 2 or 3, or C(R3)(R4)A, wherein A is an acidic functional group such as carboxyl, carboxamide substituted or unsubstituted sulfonamide, or substituted or unsubstituted tetrazole. R3 is H, saturated or unsaturated C1-C5 alkyl, C1-C5 alkoxy.Type: ApplicationFiled: September 11, 2003Publication date: May 27, 2004Inventors: Ivan Collado Cano, Samuel James Dominianni, Garret Jay Etgen, Cristina Garcia-Paredes, Richard Duane Johnston, Michael Edward Letourneau, Nathan Bryan Mantlo, Michael John Martinelli, Daniel Ray Mayhugh, Ashraf Saeed, Richard Craig Thompson, Xiaodong Wang, David Scott Coffey, Christopher Randall Schmid, Jeffrey Thomas Vicenzi, Yanping Xu